Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2000;95:353-357
© 2000 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VUORELA, P.
Right arrow Articles by HALMESMÄKI, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VUORELA, P.
Right arrow Articles by HALMESMÄKI, E.

ORIGINAL RESEARCH

Amniotic Fluid–Soluble Vascular Endothelial Growth Factor Receptor-1 in Preeclampsia

PIIA VUORELA, MD, SATU HELSKE, CARSTEN HORNIG, MSc, KARI ALITALO, MD, PhD, HERBERT WEICH, PhD and ERJA HALMESMÄKI, MD, PhD

From the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland; Department of Gene Regulation and Differentiation, Division of Molecular Biotechnology, Braunschweig, Germany; and Molecular and Cancer Biology Laboratory, Haartman Institute, University of Helsinki, Finland.

Address reprint requests to: Erja Halmesmäki, MD, PhD Departments of Obstetrics and Gynecology Helsinki University Central Hospital PL 140 Helsinki, 00029 HYKS Finland E-mail: erja.halmesmaki{at}helsinki.fi

Objective: To measure the levels of the soluble receptor for the potent angiogenic agent vascular endothelial growth factor (VEGF) in amniotic fluid (AF) in healthy and complicated pregnancies, and compare them with levels of erythropoietin, another factor upregulated by hypoxia.

Methods: We assessed amniotic fluid from the second (n = 35, gestational weeks 14–19) and third (n = 29) trimesters of healthy women, and from the third trimesters of preeclamptic (n = 22) and diabetic women with (n = 11) or without preeclampsia (n = 34) and from women with fetal growth restriction (FGR) (n = 14) for soluble VEGF receptor-1 (VEGFR-1) by enzyme-linked immunosorbent assay.

Results: In early normal pregnancy, AF-soluble VEGFR-1 levels were higher (median 22 ng/mL, range 2.3–29.5 ng/mL) than in the third trimester (median 13 ng/mL, range 0.5–32 ng/mL; P < .05). In preeclamptic women during the third trimester, levels were higher (median 20 ng/mL, range 10.5–37 ng/mL; P < .05) than healthy controls. The lowest third-trimester levels were in diabetic women (median 11 ng/mL, range 0.5–27 ng/mL). In women with preeclampsia and diabetes, AF-soluble VEGFR-1 levels remained lower (median 13, range 6–32 ng/mL; P < .05) than in women with preeclampsia alone. Amniotic fluid levels of soluble VEGFR-1 in women with FGR (median 19.5 ng/mL, range 5–40 ng/mL) did not statistically differ from those of controls. The AF levels of soluble VEGFR-1 did not correlate with those of erythropoietin. Soluble VEGFR-1 was clearly detectable (median 14 ng/mL, range 9–22 ng/mL) in culture media from placental biopsies (n = 20).

Conclusion: Preeclampsia is associated with increased levels of soluble VEGFR-1, which are independent of erythropoietin, another hypoxia-inducible factor.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
N. Steeghs, H. Gelderblom, J. o. t Roodt, O. Christensen, P. Rajagopalan, M. Hovens, H. Putter, T. J. Rabelink, and E. de Koning
Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
Clin. Cancer Res., June 1, 2008; 14(11): 3470 - 3476.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
F. Collino, B. Bussolati, E. Gerbaudo, L. Marozio, S. Pelissetto, C. Benedetto, and G. Camussi
Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1185 - F1194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger
Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. S. Gilbert, S. A. Babcock, and J. P. Granger
Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression
Hypertension, December 1, 2007; 50(6): 1142 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
V. D. Garovic, S. J. Wagner, L. M. Petrovic, C. E. Gray, P. Hall, H. Sugimoto, R. Kalluri, and J. P. Grande
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1136 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Kalluri
Proteinuria with and without Renal Glomerular Podocyte Effacement
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2383 - 2389.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al.
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K.-A. Wathen, E. Tuutti, U.-H. Stenman, H. Alfthan, E. Halmesmaki, P. Finne, O. Ylikorkala, and P. Vuorela
Maternal Serum-Soluble Vascular Endothelial Growth Factor Receptor-1 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 180 - 184.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. Ahmad and A. Ahmed
Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia
Circ. Res., October 29, 2004; 95(9): 884 - 891.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-Y. Chung, Y. Song, Y. Wang, R. R. Magness, and J. Zheng
Differential Expression of Vascular Endothelial Growth Factor (VEGF), Endocrine Gland Derived-VEGF, and VEGF Receptors in Human Placentas from Normal and Preeclamptic Pregnancies
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2484 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Sugimoto, Y. Hamano, D. Charytan, D. Cosgrove, M. Kieran, A. Sudhakar, and R. Kalluri
Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria
J. Biol. Chem., April 4, 2003; 278(15): 12605 - 12608.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D.C Felmeden, A.D Blann, and G.Y.H Lip
Angiogenesis: basic pathophysiology and implications for disease
Eur. Heart J., April 1, 2003; 24(7): 586 - 603.
[Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
S. Helske, P. Vuorela, O. Carpen, C. Hornig, H. Weich, and E. Halmesmaki
Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies
Mol. Hum. Reprod., February 1, 2001; 7(2): 205 - 210.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Obstetricians and Gynecologists.